Afabicin
Antibiotic compound
| Afabicin | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Afabicin is a novel antibiotic compound that belongs to the class of oxazolidinones. It is primarily being developed for the treatment of infections caused by Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA). Afabicin is notable for its unique mechanism of action and its potential to address antibiotic resistance.
Mechanism of Action[edit | edit source]
Afabicin works by inhibiting the bacterial enzyme fatty acid synthase II (FASII), which is essential for the synthesis of fatty acids in bacteria. This inhibition disrupts the production of bacterial cell membranes, ultimately leading to bacterial cell death. Unlike many other antibiotics, afabicin targets a pathway that is not present in human cells, which may reduce the likelihood of adverse effects.
Clinical Development[edit | edit source]
Afabicin is currently undergoing clinical trials to evaluate its efficacy and safety in treating bacterial infections. Early studies have shown promising results, particularly in treating infections caused by resistant strains of Staphylococcus aureus. The development of afabicin is part of a broader effort to find new treatments for antibiotic-resistant infections, which are a growing public health concern.
Potential Applications[edit | edit source]
Afabicin is being investigated for use in a variety of clinical settings, including:
Its ability to target resistant strains makes it a valuable candidate for treating infections that do not respond to conventional antibiotics.
Challenges and Considerations[edit | edit source]
While afabicin shows promise, there are several challenges that must be addressed in its development:
- Ensuring the compound's safety and efficacy through rigorous clinical trials.
- Overcoming potential resistance mechanisms that bacteria might develop against afabicin.
- Navigating the regulatory pathways to bring a new antibiotic to market.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
